Method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 38.95% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTRIGEL PHARMACEUTICALS INC's latest supported as-filed period reports revenue of $78.7M, 22.6% below the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 38.95% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value -22.60% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 18.25% · OPTIONAL
Level · gp.fundamentals.operating_margin
Raw value 29.95% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 17.74% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 8.70% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Inventory increased 37.8%; Inventory / revenue moved 800 bp higher.
2 evidence-backed componentsNet income changed -71.0% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Each point keeps the date investors could first observe it and its accession.
RIGL · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0000905148-26-004080SEC ↗4Sep 3, 2026Period Sep 1, 20260000905148-26-004079SEC ↗4Sep 3, 2026Period Sep 1, 20260000905148-26-004078SEC ↗4Sep 3, 2026Period Sep 1, 20260000905148-26-004077SEC ↗8-KAug 4, 2026Period Aug 4, 20260001034842-26-000053SEC ↗10-QAug 4, 2026Period Jun 30, 20260001034842-26-000052SEC ↗4Jul 10, 2026Period Jul 8, 20260000905148-26-003238SEC ↗8-KTransaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Sep 2, 2026Filed Sep 3, 2026 | Schorno Dean LEVP & Chief Financial Officer | Option ExerciseDirect | 694 | $13 | $8,814 | Form 4 ↗ |
| Sep 2, 2026Filed Sep 3, 2026 | Schorno Dean LEVP & Chief Financial Officer | Option ExerciseDirect | 620 | $19 | $11,594 | Form 4 ↗ |
| Sep 2, 2026Filed Sep 3, 2026 | Schorno Dean LEVP & Chief Financial Officer | Option ExerciseDirect | 2,000 | $24 | $48,400 | Form 4 ↗ |
| Sep 2, 2026Filed Sep 3, 2026 | Schorno Dean LEVP & Chief Financial Officer | Option ExerciseDirect | 1,286 | $24 | $31,121 | Form 4 ↗ |
| Sep 2, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating income changed -61.4% from the comparable as-filed period.
Operating margin changed -3014 basis points from the comparable as-filed period.
Revenue changed -22.6% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
SBC / revenue changed +547 basis points from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Inventory / revenue changed +800 basis points from the comparable as-filed period.
Inventory changed +37.8% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001034842-26-000045| Schorno Dean LEVP & Chief Financial Officer |
| Option ExerciseDirect |
| 694 |
| $0 |
| $0 |
| Form 4 ↗ |
| Sep 2, 2026Filed Sep 3, 2026 | Schorno Dean LEVP & Chief Financial Officer | Option ExerciseDirect | 620 | $0 | $0 | Form 4 ↗ |
| Sep 2, 2026Filed Sep 3, 2026 | Schorno Dean LEVP & Chief Financial Officer | Option ExerciseDirect | 2,000 | $0 | $0 | Form 4 ↗ |
| Sep 2, 2026Filed Sep 3, 2026 | Schorno Dean LEVP & Chief Financial Officer | Option ExerciseDirect | 1,286 | $0 | $0 | Form 4 ↗ |
| Sep 1, 2026Filed Sep 3, 2026 | Schorno Dean LEVP & Chief Financial Officer | Tax WithholdingDirect | 928 | $48 | $44,080 | Form 4 ↗ |
| Jul 8, 2026Filed Jul 10, 2026 | HANNAH ALISON L.EVP, Chief Medical Officer | Grant Or AwardDirect | 24,400 | $0 | $0 | Form 4 ↗ |